US FDA Extends Payor Communications Safe Harbor To Off-Label Uses
Executive Summary
Final guidance on drug manufacturer communications with payors adopts industry call to include exchanges about unapproved uses; they will not be considered evidence of intended use.
You may also be interested in...
Off-Label Guidance Creates ‘Safe Harbor’ For Dissemination of Certain Info To HCPs
The FDA's revised draft guidance on scientific communications to health care providers about unapproved uses of products describes the studies that are likely to be scientifically sound and clinically relevant. The agency also gives recommendations on presenting off-label information on web pages and in exhibit halls.
Preapproval Information Exchange With Payers: Guidelines Codified In Omnibus Spending Bill
Legislation, known as PIE Act, does not force manufacturers to share information on pricing or economic models with payers but aligns with the requirements in US Food and Drug Administration guidance.
Preapproval Information Exchange Between Sponsors, Insurers Clarified In House User Fee Bill
By codifying FDA guidance, pending legislation aims to encourage industry to become more comfortable with even unsolicited communications to payers about investigational drugs.